Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines.
about
Induction of thrombospondin-1 partially mediates the anti-angiogenic activity of dexrazoxaneDexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone.Dexrazoxane for the treatment of chemotherapy-related side effects.Scavenging effects of dexrazoxane on free radicals.Anthracycline cardiotoxicity: from bench to bedside.Blood-brain barrier disruption and oxidative stress in guinea pig after systemic exposure to modified cell-free hemoglobin.Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cellsIntracellular distribution of peroxynitrite during doxorubicin cardiomyopathy: evidence for selective impairment of myofibrillar creatine kinase.Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin.Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group.Cardiac protective effects of dexrazoxane on animal cardiotoxicity model induced by anthracycline combined with trastuzumab is associated with upregulation of calpain-2.Dexrazoxane Shows No Protective Effect in the Acute Phase of Reperfusion during Myocardial Infarction in PigsOxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.Iron chelators with topoisomerase-inhibitory activity and their anticancer applications.Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric OncologSynthetic and natural iron chelators: therapeutic potential and clinical useApoptotic transition of senescent cells accompanied with mitochondrial hyper-function.Matricellular protein CCN1 mediates doxorubicin-induced cardiomyopathy in mice.Visnagin-a new protectant against doxorubicin cardiotoxicity? Inhibition of mitochondrial malate dehydrogenase 2 (MDH2) and beyond.The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells.Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity.2-[3,5-Dioxo-4-(pyridin-3-yl)piperazin-1-yl]acetic acid.Development and Validation of New RP-HPLC Method for the Determination of Dexrazoxane.The effect of the catalytic topoisomerase II inhibitor dexrazoxane (ICRF-187) on CC9C10 hybridoma viability and productivity.Preventing the cardiotoxicity of anthracyclines by dexrazoxane
P2860
Q24314623-4206F249-35B6-4142-8367-617C3975C32CQ28361976-12E8ABDB-7249-42F5-970A-144FBECC66DEQ33341069-4E7167FE-178D-4C09-A41C-927E1DE466A4Q34211957-54A95D5D-8D52-4B7C-AF94-60C30A69A21AQ34255271-16FE603A-C67D-4ED3-8A60-23B84B6D554FQ34477415-E082CCE1-225B-4880-9ABD-43A6D75527BEQ34756190-DBC1DB48-6371-46BF-BF06-05DB16E85D71Q35014803-532FEA80-E6B4-4235-AB6C-93E9FF128A3AQ35044069-0FE1D53B-3A43-4503-92BF-EB3023B19AE0Q35550223-2631C135-4DCF-4BD4-9F71-F80B64293B76Q35947024-FADB5E53-587E-494A-8542-AE78481D6596Q36153375-B086FE6C-8C88-49AC-964B-D197EDB3BDC8Q36230443-D9750F96-1F25-4AC7-B67A-DDA8C1F60978Q36568908-D4EB13C0-328E-4196-A269-026B75159261Q36568915-D51EBC70-BE5E-4F00-A001-575A5D160809Q36914391-1E57A784-FF07-4486-B4BD-480E8473D9F5Q37290073-0581A453-FD2D-4D03-BC40-1A456E7C82ACQ37317537-1F8E0D07-6F37-4B97-BD23-40340E5BFFDAQ37392811-9F6D290B-DE24-439D-B765-4B88E4F228C5Q38800300-86267F1E-9BB0-4097-8331-FE8C308E40B6Q38927458-C37FFC68-ED09-4AE6-B386-285621896F41Q39264180-CC71B373-7A5B-4E0B-9038-679D77B350E3Q41828829-F61D59AC-2BF5-4C08-8D3C-F90193D09242Q41886287-1104E629-3851-4881-924A-7276EF5F3A33Q42326932-9062D24C-56A6-40AA-AF62-97D1467553BAQ42764756-047D3E23-3183-40FA-83DC-05FC2FEF3E48
P2860
Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines.
@en
type
label
Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines.
@en
prefLabel
Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines.
@en
P2093
P1476
Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines
@en
P2093
B B Hasinoff
E H Herman
K Hellmann
V J Ferrans
P577
1998-02-01T00:00:00Z